Skip to main navigation
  • About
  • Pipeline
  • Patients
  • Investors
  • Contact Us

Investor Relations

  • Investors
  • Press Releases
  • Event Calendar
  • Stock Info
  • Governance
  • Financial Info
  • Shareholder Services
  • Presentations

Shareholder Tools


  • Facebook
  • Google
  • LinkedIn
  • Twitter

Press Releases

Keyword Search

01/18/23
Bellerophon Therapeutics Announces Completion of Enrollment in Phase 3 REBUILD Study for INOpulse® in Fibrotic Interstitial Lung Disease
01/05/23
Bellerophon Therapeutics Announces License Agreement for the Commercialization of INOpulse® in Greater China with Baylor BioSciences
© 2023 Bellerophon Therapeutics. All rights reserved.
  • Site Map
  • Terms of Use
  • Privacy Policy